亚洲国产日韩视频_亚洲黄色av网址_欧美在线网站_黄品汇mba智库黑科技_free性欧美另类高清_丰满人妻熟妇乱又伦精品_九月婷婷丁香_无码6080yy私人影院在线看

Shanghai, China – May 30, 2025 –Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”), a leading Chinese biopharmaceutical company, today announced an expanded strategic collaboration with Partex, a leader in AI-driven pharmaceutical innovation, to jointly develop and out-license AK0658, a preclinical-stage ATR inhibitor demonstrating best-in-class potential. This follow-up partnership builds on the successful launch of their initial collaboration focused on autotaxin inhibitor AK0707.

Under the terms of the new agreement, ArkBio will lead preclinical development and early clinical strategy for AK0658, while Partex will deploy its proprietary Asset42 AI platform to unlock the full life cycle management potential of AK0658 across a range of new indications as well as lead the identification of strategic partners and drive global out-licensing efforts.

AK0658 is an advanced preclinical-stage ATR inhibitor with improved selectivity, enhanced pharmacokinetic (PK) properties, and superior in-vivo efficacy compared to Berzosertib, one of the most prominent ATR inhibitors in development. The compound represents a promising therapeutic candidate for multiple cancer indications where DNA damage response (DDR) pathways are implicated.

"AK0658 represents a highly promising candidate with the potential to leverage synthetic lethality approaches in cancers with DDR deficiencies," said Dr. Haiqing Yuan, Chief Operating Officer at ArkBio. "Partex has proven to be an outstanding partner in harnessing the power of artificial intelligence to unlock new opportunities for our pipeline. We are confident that this expanded collaboration will accelerate the global reach of AK0658 and bring transformative therapies to patients in need."

"Building on the momentum from our AK0707 partnership, we are excited to take this next step with ArkBio," said Dr. Frank Grams, Chief Commercial Officer at Partex. "AK0658 is a compelling candidate with strong early data, and we believe our AI-driven approach will significantly accelerate the discovery of optimal indications and ideal partners for this asset."

This ongoing collaboration highlights both companies' commitment to utilizing cutting-edge AI technology to accelerate global development and commercialization of innovative therapies.

About ArkBio
Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) is a Chinese biopharmaceutical company focused on developing novel therapies for unmet medical needs, particularly in pediatric and respiratory diseases. The company is also actively seeking out-licensing opportunities for innovative oncology assets such as AK0658 to maximize their global therapeutic potential.

About Partex
Partex is a leading innovator in pharmaceutical AI, specializing in data-driven drug development and out-licensing strategies. Its proprietary platform, Asset42, harnesses advanced machine learning to identify new therapeutic uses, optimize clinical potential, and streamline licensing transactions globally.

For more information about the company, please visit our website：www.m10390.cn

Investor Inquiries：IR@arkbiosciences.com